1. Germany Stocks

  2. •

    Healthcare

  3. •

    Medical - Diagnostics & Research
Stratec SE

Stratec SE

SBS.DE
Stratec SEDE flagDeutsche Börse
17.62
EUR
-0.50
- -
214.19MMarket Cap
Stratec SE
SBS.DE
(Deutsche Börse)

Recent

price

17.62

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
9.31
10.03
10.49
10.89
12.31
12.44
15.6
17.46
15.73
17.86
20.73
23.73
22.64
22.25
21.19
20.64
20.07
Revenue per Share
1.14
1.32
1.06
1.32
1.68
1.87
1.65
2.16
0.75
1.2
2.09
3.3
2.41
1.26
1.32
-0.02
-0.28
Basic EPS, GAAP
-0.54
0.7
0.07
1.17
2.81
1.45
0.53
1.2
-0.63
-0.47
0.52
3.57
-0.72
0.16
2.51
-1.37
0.63
Free Cash Flow per Basic Share
0.45
0.5
0.55
0.56
0.6
0.7
0.75
0.77
0.8
0.82
0.84
0.9
0.95
0.97
0.55
0.6
- -
Dividend per Share
2.15
2.32
2.2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Book Value per Share
5.38
4.83
5.19
5.7
6.95
8.32
1.99
3.97
4.52
5.16
6.96
9.61
11.52
10.25
10.58
10.64
10.54
Tangible Book Value per Share
11
12
12
12
12
12
12
12
12
12
12
12
12
12
12
12
12
Basic Weighted Avg Shares
107
117
123
128
145
147
185
207
188
214
250
287
275
270
258
251
244
Sales/Revenue/Turnover
16.5
18.74
12.7
15.23
16.6
18.3
13.05
11.76
8.19
8.5
13.62
17.56
15.57
10.78
10.94
4.26
3.03
Operating Margin (%)
3
4
6
7
8
6
11
18
22
19
23
18
17
18
19
25
24
Depreciation Expense
13
15
12
15
20
22
19
26
9
14
25
40
29
15
16
- -
-3
Net Income, GAAP
25.71
27.68
18.76
19.94
17.82
18.73
14.66
8.29
21.15
13.47
13.89
14.68
25.24
28.66
27.2
104.99
296.02
Effective Tax Rate (%)
12.22
13.11
10.15
12.1
13.65
15.03
10.54
12.36
4.78
6.74
10.07
13.91
10.64
5.68
6.22
-0.1
-1.39
Profit Margin (%)
54
48
50
57
74
89
12
88
88
93
121
142
152
138
133
160
151
Working Capital
7
9
7
7
4
4
3
62
69
90
104
79
80
94
86
108
- -
LT Debt
72
80
88
97
112
129
142
158
152
159
173
206
227
237
243
237
237
Total Equity
18.61
18.36
13.48
15.33
17.25
16.77
11.73
10.27
5.41
6.57
10.88
14.86
10.36
5.88
5.37
-0.14
-12.1
Return on Invested Capital (%)
47.53
45.17
35.66
57.33
96.78
108.68
39.5
33.44
12.17
16.36
23.03
37.59
31.15
14.41
13.72
-0.31
-188.12
Return on Capital (%)
54.64
59.27
47.27
82.59
167.77
186.77
164.43
215.58
75.09
120.34
208.64
329.81
240.66
126.42
131.77
-1.99
-55.95
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
25
- -
LT Borrowings
- -
99
- -
LT Finance Leases
- -
9
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
12
12
12
Market Capitalization
348
273
208

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
208
213
197
Cash, Cash Equivalents & STI
24
24
25
Accounts Receivable, Net
42
57
43
Inventories
126
110
114
Total Current Liabilities
50
54
45
Payables & Accruals
- -
- -
- -
ST Debt
- -
25
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
6.45%
6.83%
-2.15%
Free Cash Flow
129.3%
323.67%
-154.59%
Net Income, GAAP
-2.27%
-22.56%
-101.51%
Sales/Revenue/Turnover
6.1%
0.32%
-2.62%
Total Cash Common Dividend
0.25%
-3.66%
9.06%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
51
68
60
81
258
2025
60
58
57
75
251
2026
53
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.04
0.29
0.06
- -
1.32
2025
0.12
- -
0.12
- -
-0.02
2026
-0.14
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.55
2025
- -
- -
- -
- -
0.6
2026
- -
- -
- -
- -
- -
Similar Companies
Tecan Group AG (0QLN.L)
Quest Diagnostics Incorporated (0KSX.L)
Illumina, Inc. (ILMN)
Lonza Group AG (LZAGF)
Danaher Corporation (0R2B.L)
Many Bright Ideas Technologies Inc. (MBGNF)
Business
Stratec SE specializes in designing and manufacturing fully automated analyzer systems, software, and complex consumables for clinical diagnostics, in vitro diagnostics (IVD), and biotechnology applications. The company's core product offerings include automated analyzer systems for molecular diagnostics, immunoassays, hematology, and transfusion diagnostics; integrated laboratory software and middleware solutions for data management and system control; smart consumables including sample preparation solutions and complex reagents; and system software that supports diagnostic workflows. Stratec operates primarily as an original equipment manufacturer (OEM) supplying well-known global diagnostic companies, with its products used by clinical laboratories, blood banks, and research institutes worldwide. Founded in 1979 and headquartered in Birkenfeld, Germany, the company has expanded its geographic focus to include growing operations and sales channels in the United States, Asia-Pacific, and Europe. Recent major developments include the strengthening of its development pipeline through new cooperation agreements, such as a comprehensive strategic partnership in immunodiagnostics aimed at enhancing and extending product lifecycles. Stratec completed the final development milestone for a customer-focused product line in transfusion diagnostics in 2024 and advanced several projects involving complex consumable production in the US. The company has increased its local presence in key growth markets by establishing new sales and production units in Asia and expanding distribution channels in the United States post its integration of Natech Group, creating cross-selling opportunities across the group. In 2024, Stratec reported resilient sales of €257.6 million with an adjusted EBIT margin improvement to 13.0%, driven by strong service parts and consumables sales alongside licensing and development revenues. Operational efficiency measures and structural changes contributed to margin enhancement despite pandemic-related demand disruptions and elevated customer inventory levels. These strategic initiatives and operational improvements underscore the company’s continued focus on innovation, global expansion, and long-term partnerships within the diagnostics industry.